OA10.04 Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance after Chemo-immunotherapy for ES-SCLC: DeLLphi-303 Phase 1b Study
Shu Ping Lau, M-J. Ahn, Mor Moskovitz, Michael Pogorzelski, Simon Haefliger, K. G. Paulson, Andrew Parkes, Y. Zhang, Anahita Hamidi, Martin Wermke
Topics & Concepts
MedicineFirst lineImmunotherapyLine (geometry)OncologyFirst line treatmentPD-L1Phase (matter)Internal medicineImmunologyImmune systemChemotherapyGeometryMathematicsChemistryOrganic chemistryLung Cancer Research StudiesNanoparticle-Based Drug DeliveryPeptidase Inhibition and Analysis